MBX Biosciences, Inc.

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEP™, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients. Our PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. We are advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. Our product candidates and programs include:

Current securities

1. Regulation FD Disclosure · Other EventsAug 27, 2026
2. SCHEDULE 13G/A filingAug 14, 2026
3. 10-Q filingAug 6, 2026
4. Results of Operations and Financial Condition · Regulation FD Disclosure · Other EventsAug 6, 2026
5. 4 filingAug 4, 2026